Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

IntroductionThe objective of this study was to investigate the effects of tumor necrosis factor (TNF)-α inhibitors on circulating T helper-type 17 (Th17) cells and Th17-related cytokines in patients with rheumatoid arthritis (RA).MethodsThe frequencies of circulating Th17 cells and serum levels of Th17-related cytokines were determined using flow cytometry analysis and ELISA, respectively, in 48 RA patients both before (baseline) and six months after anti-TNF-α therapy. Therapeutic response was evaluated using European League Against Rheumatism (EULAR) response criteria.ResultsSignificantly higher baseline frequencies of circulating Th17 cells and serum levels of interleukin (IL)-6, IL-17, IL-21, IL-23 and TNF-α were observed in active RA patients than in 12 healthy controls (all P < 0.001). After anti-TNF-α therapy, 36 patients (75%) were EULAR responders (20 good responders and 16 moderate responders) and 12 (25.0%) were non-responders. The mean levels of circulating Th17 cells and IL-17 significantly decreased (1.13% vs. 0.79%; 43.1 pg/ml vs. 27.8 pg/ml; respectively, both P < 0.001) in parallel with clinical remission in responders. Levels of IL-6, IL-21, IL-23 and TNF-α were significantly decreased after anti-TNF-α therapy in responders. In contrast, the mean levels of circulating Th17 cells and IL-17 significantly increased after anti-TNF-α therapy (2.94% vs. 4.23%; 92.1 pg/ml vs. 148.6 pg/ml; respectively, both P < 0.05) in non-responders. Logistic regression analysis identified a high baseline level of IL-17 as a significant predictor of poor therapeutic response.ConclusionsThe beneficial effect of anti-TNF-α therapy might involve a decrease in Th17-related cytokines in responders, whereas rising levels of circulating Th17-cells and IL-17 were observed in patients with an inadequate response to anti-TNF-α therapy.

• Publication year

  2011

• Venue

  Arthritis Research & Therapy

• Publication date

  2011-07-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/ar3431PMID 21801431PMCID 3239366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.

  2011cited by this paper
• Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.

  2011cited by this paper
• Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor.

  2011cited by this paper
• Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production.

  2011cited by this paper
• 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis.

  2010cited by this paper
• Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression.

  2010cited by this paper
• Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial

  2010cited by this paper
• LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.

  2010cited by this paper
• Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.

  2010cited by this paper
• Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF.

  2010cited by this paper
• Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease.

  2010cited by this paper
• The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients

  2010cited by this paper
• Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

  2010cited by this paper
• Predicting response to anti-TNF treatment in rheumatoid arthritis patients.

  2009cited by this paper
• Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis.

  2009cited by this paper
• Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

  2009cited by this paper
• Role of TL1A in the Pathogenesis of Rheumatoid Arthritis1

  2009cited by this paper
• Human Th17 cells

  2008cited by this paper
• Three-dimensional and thermal surface imaging produces reliable measures of joint shape and temperature: a potential tool for quantifying arthritis

  2008cited by this paper
• IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage1

  2008cited by this paper
• IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

  2008cited by this paper
• Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

  2008cited by this paper
• Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases.

  2008cited by this paper
• Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis

  2007cited by this paper
• Cells of the synovium in rheumatoid arthritis. T lymphocytes

  2007cited by this paper
• TNF-α Drives Human CD14+ Monocytes to Differentiate into CD70+ Dendritic Cells Evoking Th1 and Th17 Responses

  2007cited by this paper
• Distinct regulation of interleukin-17 in human T helper lymphocytes.

  2007cited by this paper
• Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway.

  2007cited by this paper
• IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells

  2007cited by this paper
• Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis

  2007cited by this paper
• IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

  2007cited by this paper
• TH-17 cells in the circle of immunity and autoimmunity

  2007cited by this paper
• Cells of the synovium in rheumatoid arthritis. Macrophages

  2007cited by this paper
• Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses

  2007cited by this paper
• Joint inflammation and cytokine inhibition in rheumatoid arthritis

  2006cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction

  2006cited by this paper
• Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

  2006cited by this paper
• A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

  2005cited by this paper
• TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques1

  2005cited by this paper
• Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin

  2005cited by this paper
• Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

  2005cited by this paper
• Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).

  2005cited by this paper
• Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

  2004cited by this paper
• Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor κB-dependent pathway in patients with rheumatoid arthritis

  2004cited by this paper
• TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

  2003cited by this paper
• Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

  2003cited by this paper
• TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

  2003cited by this paper
• Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

  2002cited by this paper
• Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro

  2002cited by this paper
• Cytokine pathways and joint inflammation in rheumatoid arthritis.

  2001cited by this paper
• Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes.

  2001cited by this paper
• IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis

  2001cited by this paper
• IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.

  1998cited by this paper
• Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.

  1996cited by this paper
• Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

  1995influential reference
• Revised criteria for the classification of rheumatoid arthritis.

  1989cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.

  2026cites this paper
• Advancing psoriasis management through the application of secondary metabolites: A detailed review of phytoconstituents and their multifaceted mechanisms

  2026cites this paper
• Interaction between TNF inhibitors and serum IL-17 levels and susceptibility to rheumatoid arthritis

  2026cites this paper
• Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

  2026cites this paper
• A Potential Central Hub of Histamine in the Microbiota–Gut–Joint Axis in Rheumatoid Arthritis: Mechanisms and Translational Implications

  2026cites this paper
• First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

  2025cites this paper
• IL17 genetic variants impact the response and safety of TNFi treatment in rheumatoid arthritis patients from Bahia, Brazil.

  2025cites this paper
• Case Report: Treating one autoimmune disease induces another: the paradox of TNF-alpha inhibitor therapies

  2025cites this paper
• Promising TNF-α inhibitors: Targeting pathogenic TNF-α/TNFR signaling to restore Th17/Treg balance in rheumatoid arthritis

  2025cites this paper
• The potency of cell-based assays to predict response to TNF inhibitor therapy

  2025cites this paper
• Remdesivir alleviates joint damage in collagen-induced arthritis and inhibits inflammatory cell death of RA synovial fibroblasts.

  2025cites this paper
• Therapeutic Effects of Two Different Molecular Weights of Orally Administered Hyaluronan, Both as Monotherapy and in Combination with Methotrexate in a Rat Model of Arthritis

  2025cites this paper
• Type 1 interferon signature and allograft inflammatory factor-1 contribute to refractoriness to TNF inhibition in ankylosing spondylitis

  2025cites this paper
• Recombinant adeno-associated virus with anti-tumor necrosis factor-alpha in an experimental autoimmune uveitis model.

  2025cites this paper
• Suppressive Effects of JTE-151, a Novel Orally Available RORγ Antagonist, in Experimental Models of Rheumatoid Arthritis.

  2025cites this paper
• Discovery and preclinical evaluation of KYS202004A, a novel bispecific fusion protein targeting TNF-α and IL-17A, in autoimmune disease models.

  2024cites this paper
• Ex-vivo Cell-based Assay for Assessment of Response to TNF Inhibitors in Patients with Rheumatic Diseases.

  2024cites this paper
• C-reactive protein lowers the serum level of IL-17, but not TNF-α, and decreases the incidence of collagen-induced arthritis in mice

  2024cites this paper
• Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls

  2024cites this paper
• Inflammation and gut dysbiosis as drivers of CKD–MBD

  2023cites this paper
• TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life

  2023cites this paper
• Tumor necrosis factor-α inhibitor-related immune disorders.

  2023cites this paper
• Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis

  2023cites this paper
• Indole-3-pyruvic acid alleviates rheumatoid arthritis via the aryl hydrocarbon receptor pathway

  2023cites this paper
• The role of interleukin 17 in the pathogenesis of rheumatoid arthritis. Are there any prospects for the use of IL-17 inhibitors?

  2023cites this paper
• Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis.

  2023cites this paper
• Temporal dynamics of Th17 responses to Candida albicans in rheumatoid arthritis: Implications for immunity and treatment

  2023cites this paper
• Pivotal Role of Intestinal Microbiota and Intraluminal Metabolites for the Maintenance of Gut–Bone Physiology

  2023cites this paper
• Plasma interleukin-23 and circulating IL-17A+IFNγ+ ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritis

  2022cites this paper
• IL‐3 regulates the differentiation of pathogenic Th17 cells

  2022cites this paper
• Analysis of Some Candidate Genes for Rheumatoid Arthritis of the Iraqi Population

  2022cites this paper
• TNF-α Affects Signature Cytokines of Th1 and Th17 T Cell Subsets through Differential Actions on TNFR1 and TNFR2

  2022cites this paper
• Synovial Inflammatory Pathways Characterize Anti‐TNF–Responsive Rheumatoid Arthritis Patients

  2022cites this paper
• Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis

  2022cites this paper
• CCR4 plays a pivotal role in Th17 cell recruitment and expansion in a mouse model of rheumatoid arthritis.

  2022cites this paper
• Gut Microbiota and Bone Diseases: A Growing Partnership

  2022cites this paper
• miR-10 and Its Negative Correlation with Serum IL-35 Concentration and Positive Correlation with STAT5a Expression in Patients with Rheumatoid Arthritis

  2022cites this paper
• T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy

  2022cites this paper
• Relationship of cytokine level dynamics with longterm results of early rheumatoid arthritis therapy

  2022cites this paper
• CTLA-4 POLYMORPHISM ALONG WITH PROINFLAMMATORY CYTOKINES IN AUTOIMMUNE THYROIDITIS DISEASE.

  2022cites this paper
• Multiple Sclerosis and Autoimmunity: A Veiled Relationship

  2022cites this paper
• Levels of Pathogenic Th17 and Th22 Cells in Patients with Rheumatoid Arthritis

  2022influential citation
• Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis

  2022cites this paper
• Ovariectomy induces bone loss via microbial-dependent trafficking of intestinal TNF+ T cells and Th17 cells.

  2021cites this paper
• High Concentrations of Etanercept Reduce Human Islet Function and Integrity

  2021cites this paper
• Identification of human immune cell subtypes most responsive to IL-1β–induced inflammatory signaling using mass cytometry

  2021cites this paper
• Estrogen deficiency and the pathogenesis of osteoporosis

  2021cites this paper
• Protective effect of Ellipticine in ovalbumin (OVA)-induced murine model of allergic rhinitis via dual inhibition of COX-2 and NF-κB

  2021cites this paper
• Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When?

  2021cites this paper
• Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

  2021cites this paper
• Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis

  2021cites this paper
• Gut microbiota and bone metabolism

  2021cites this paper
• Immunologic Parameters for Disease Activity in Rheumatoid Arthritis.

  2021cites this paper
• Protective effect of corynoline in a murine allergic rhinitis model via inhibition of caspase‐1/NF‐κB

  2020cites this paper
• Synovial fluid CD69+CD8+ T cells with tissue‐resident phenotype mediate perforin‐dependent citrullination in rheumatoid arthritis

  2020cites this paper
• Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis

  2020cites this paper
• Current and novel therapeutic targets in the treatment of rheumatoid arthritis

  2020cites this paper
• Identification of Human Immune Cell Subtypes Most Vulnerable to IL-1β-induced Inflammatory Signaling Using Mass Cytometry

  2020cites this paper
• New Findings on Autoimmune Etiology of Idiopathic Granulomatous Mastitis: Serum IL-17, IL-22 and IL-23 Levels of Patients

  2020cites this paper
• Juntendo Medical Journal

  2020cites this paper
• Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes

  2020cites this paper
• Treg Heterogeneity, Function, and Homeostasis

  2020cites this paper
• Clinical Efficacy and Factors Predictive of the Therapeutic Effect of the TNF Inhibitor Golimumab in Patients with Rheumatoid Arthritis

  2020cites this paper
• T helper 17 cells and interleukin-17 in patients with rheumatoid arthritis

  2019influential citation
• Investigating the Balance between Th17/Treg Cells in Rheumatoid Arthritis and its Association with Disease Activity

  2019cites this paper
• Distant Immune and Microbiome Regulation

  2019cites this paper
• Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

  2019cites this paper
• IL-1β, IL-17A, CRP and biologics history might serve as potential markers for clinical response to etanercept in rheumatoid arthritis patients

  2019cites this paper
• Systemic effects of IL-17 in inflammatory arthritis

  2019cites this paper
• Functional MIF promoter haplotypes modulate Th17‐related cytokine expression in peripheral blood mononuclear cells from control subjects and rheumatoid arthritis patients

  2019cites this paper
• cIAP1/2 inhibition synergizes with TNF inhibition in autoimmunity by down-regulating IL-17A and inducing Tregs

  2019cites this paper
• Ibudilast Inhibits Chemokine Expression in Rheumatoid Arthritis Synovial Fibroblasts and Exhibits Immunomodulatory Activity in Experimental Arthritis

  2019cites this paper
• Investigating the expression and function of IL-17A+ and IL-17F+ CD4+ T cells in human health and inflammatory arthritis

  2019cites this paper
• Amelioration of clinical symptoms of patients with refractory rheumatoid arthritis following treatment with autologous bone marrow-derived mesenchymal stem cells: A successful clinical trial in Iran.

  2019cites this paper
• T cell polarization influences the development of IBD-associated neoplasia

  2019cites this paper
• Th17 Cells

  2019cites this paper
• Lactate Buildup at the Site of Chronic Inflammation Promotes Disease by Inducing CD4+ T Cell Metabolic Rewiring

  2019cites this paper
• Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses

  2019cites this paper
• NF-κB-driven miR-34a impairs Treg/Th17 balance via targeting Foxp3.

  2019cites this paper
• Investigation of the adaptive immune response in immune-mediated diseases

  2019influential citation
• Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ‐61178104, a Novel Tumor Necrosis Factor‐Alpha and Interleukin‐17A Bispecific Antibody, in Healthy Subjects

  2019cites this paper
• inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental

  2018cites this paper
• Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis

  2018cites this paper
• ABT‐122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin‐17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate

  2018cites this paper
• Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

  2018cites this paper
• ON HYGIENE HYPOTHESIS AND APPROACHES TO MODULATING THE MICROBIOME

  2018cites this paper
• Functional and phenotypic heterogeneity of Th17 cells in health and disease

  2018cites this paper
• TNF&agr; in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases

  2018cites this paper
• Retinoid interferon-induced mortality19 (GRIM19) inhibits proliferation and invasion in rheumatoid arthritis fibroblast-like synoviocytes.

  2018cites this paper
• No effect of anti-TNF-α treatment on serum IL-17 in patients with rheumatoid arthritis

  2018cites this paper
• Protective Effect of Norcantharidin on Collagen-Induced Arthritis Rats

  2018cites this paper
• Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A

  2018cites this paper
• Anti-Inflammatory Effects of p-Coumaric Acid, a Natural Compound of Oldenlandia diffusa, on Arthritis Model Rats

  2018cites this paper
• IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis

  2018cites this paper
• Modulation of T-cell responses by anti-tumor necrosis factor treatments in rheumatoid arthritis: a review

  2018cites this paper
• Pharmacodynamic biomarkers and differential effects of TNF‐ and GM‐CSF‐targeting biologics in rheumatoid arthritis

  2018cites this paper
• Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis

  2018cites this paper
• IL-6 is an independent predictive factor of drug survival after dose escalation of infliximab in patients with rheumatoid arthritis

  2018influential citation
• Microbiota‐Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis

  2018cites this paper
• What is the best treatment target in axial spondyloarthritis: tumour necrosis factor &agr;, interleukin 17, or both?

  2018cites this paper